Momelotinib was associated with greater anemia-related benefits in patients with myelofibrosis, according to an analysis presented at the 12th Annual Meeting of the Society of Hematologic Oncology (SOHO 2024).
“These data demonstrate that momelotinib was associated with greater anemia-related benefits in both JAK inhibitor–naive and –experienced patients with myelofibrosis,” the authors wrote in the abstract.
The analysis was led by Ruben Mesa, MD, President and Executive Director of the Atrium Health cancer service line, and presented at SOHO 2024 by Brian Strouse, MS, Global Scientific Director of Medical Affairs at GSK.
Anemia occurring in patients with myelofibrosis is “often managed using red blood cell (RBC) transfusions” according to the authors, adding that “RBC transfusions are associated with lower quality of life and increased burden to patients and health care systems.”
Dr, Mesa and colleagues analyzed included 429 evaluable patients from the SIMPLIFY-1 trial and 195 evaluable patients from the MOMENTUM trial. The researchers investigated the transfusion burden in patients with JAK inhibitor–naive and –experienced myelofibrosis.
In the SIMPLIFY-1 study, patients were either treated with momelotinib or ruxolitinib. Patients treated with momelotinib needed 0.10 fewer units of blood every 28 days on average, while those treated with ruxolitinib needed 0.39 more units. Additionally, 87% of patients on momelotinib either maintained (68%) or improved (19%) their transfusion needs, compared with 54% of patients on ruxolitinib (maintained 44%; improved 11%).
In the MOMENTUM study, patients were either treated with momelotinib or danazol. Patients treated with momelotinib needed 0.86 fewer units of blood every 28 days on average, while those on danazol needed 0.28 fewer units. In this study, 85% of patients on momelotinib either maintained (19%) or improved (65%) their transfusion needs, compared to 63% of patients on danazol (maintained 11%; improved 52%).
“Across both trials, ≥85% of patients treated with momelotinib had maintained or improved transfusion intensity,” the authors concluded.
Funding was provided by GSK.
Reference
Ruben M, Perkins A, Tee Goh Y, et al. Transfusion intensity over time in patients from the phase 3 SIMPLIFY-1 and MOMENTUM trials of momelotinib. Abstract MPN-88. Presented at the Twelfth Annual Meeting of the Society of Hematologic Oncology. September 4-7, 2024; Houston, Texas.
Leave feedback about this